IBS & Myofascial Pain — The Viscero-Somatic Connection

The gut and the abdominal muscle wall share the same pain pathways — a neuroanatomical reality that explains one of the most clinically confusing overlaps in medicine. Visceral afferents from the gut and somatic afferents from the abdominal musculature converge on the same second-order neurons in the dorsal horn of the spinal cord. When the gut is chronically inflamed or sensitized — as in IBS — these shared neurons become hyperexcitable, lowering the threshold for pain arising from the abdominal wall muscles. The result: an IBS patient develops abdominal trigger points not because of direct muscle injury, but because their gut has sensitized their spinal cord.

The gut-brain axis — the bidirectional communication network between the enteric nervous system, the central nervous system, and the immune system — perpetuates myofascial pain in IBS patients. Gut microbiome dysbiosis, which is increasingly recognized in IBS, elevates systemic inflammatory markers that lower pain thresholds throughout the body. Stress activates both the HPA axis (driving cortisol release and muscle tension) and the enteric nervous system (altering gut motility and visceral sensitivity). This creates the stress-gut-muscle triangle: a vicious cycle in which psychological stress worsens IBS symptoms, IBS symptoms worsen central sensitization, and central sensitization amplifies both gut and muscle pain.

One of the most commonly missed diagnoses in IBS is abdominal wall myofascial pain syndrome. Trigger points in the rectus abdominis, internal and external obliques, and iliopsoas can produce pain that is difficult to distinguish from visceral pain — cramping, bloating-like discomfort, and urgency. Clinical experience suggests that a substantial proportion of patients with IBS have clinically significant abdominal wall trigger points, though precise prevalence estimates vary across studies. Many IBS patients who have undergone extensive GI investigations without a structural explanation for their pain may have an abdominal wall MPS component — a condition that often responds well to trigger point release once correctly identified using the simple Carnett's test.

The treatment revolution in IBS-MPS management is the recognition that integrated care — combining gastroenterology medical management, physiotherapy trigger point treatment, dietitian-guided low FODMAP therapy, and psychological intervention — produces outcomes superior to any single-discipline approach. Low FODMAP diet reduces gut-driven mast cell activation that sensitizes abdominal wall nociceptors. Trigger point release reduces the somatic afferent bombardment that perpetuates visceral hypersensitivity. Gut-directed hypnotherapy reduces central sensitization shared by both conditions. The gut-muscle pain cycle can be interrupted at multiple points simultaneously — and that is precisely what integrated treatment achieves.

The epidemiological overlap between IBS and MPS is striking. IBS is one of the most common functional GI disorders, with global prevalence estimates ranging from roughly 4% to 10% depending on diagnostic criteria, and a higher prevalence in women. Studies of IBS cohorts consistently show elevated rates of widespread musculoskeletal pain, fibromyalgia, and trigger point sensitivity — consistent with shared central sensitization. Patients with both IBS and MPS tend to report higher pressure pain sensitivity at remote sites (the hand, the leg) than patients with either condition alone, suggesting additive central nervous system amplification. The economic burden of the IBS-MPS overlap is substantial: these patients tend to have higher healthcare utilization, more missed workdays, and lower quality of life scores than patients with either condition in isolation.

Mast cell research has clarified the local tissue mechanism linking IBS gut inflammation to abdominal wall MPS. Mast cells in the intestinal mucosa are activated by IBS triggers — stress, specific foods, gut dysbiosis — and release histamine, prostaglandins, and tryptase. These mediators are not confined to the gut lumen; they enter the mesenteric circulation and directly sensitize abdominal wall nociceptors. This explains the clinical observation that IBS flares reliably worsen abdominal trigger points, and that dietary interventions that reduce IBS symptoms (particularly low FODMAP) also reduce abdominal trigger point sensitivity. The mast cell is the molecular bridge between the gut and the muscle wall.